Maravai Lifesciences Holdings, Inc. (Maravai) has announced its preliminary unaudited 2024 revenue, expecting to report total revenue near the mid-point of the previously announced guidance range of $255.0 million and $265.0 million. This indicates a potential strong performance in 2024.
The company plans to announce its fourth quarter and full year 2024 financial and operating results after the market closes on Tuesday, February 25, 2025. The conference call and webcast will be hosted on the same day at 2:00 p.m. PT/ 5:00 p.m. ET.
Maravai is a global provider of life science reagents and services to researchers and biotech innovators, delivering critical products to enable the development of drug therapies, diagnostics, and novel vaccines, as well as to support research on human diseases.
The preliminary revenue results for the full year 2024 are subject to change, as the company has not yet completed its financial close process for the year. However, based on the preliminary results, it seems that Maravai has performed well in 2024.
It's worth noting that Maravai's companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world's leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies. This indicates a strong market position and potential for continued growth and success. Today the company's shares have moved 1.3% to a price of $6.13. For more information, read the company's full 8-K submission here.
